GLP-1RA Medications Associated with Reduced Cardiac Events and Mortality in Patients with Obesity and Autoimmune Disease

# GLP-1 Drugs Tied to Lower Heart Risks in People with Obesity and Autoimmune Disease

A new study suggests that popular weight-loss and diabetes medications may offer significant cardiovascular benefits for a specific high-risk group: adults with both obesity and an autoimmune disease.

> **"Those taking GLP-1RA medications had lower rates of emergency department visits and serious cardiac events compared to those not taking these medications."**

The research, presented at the American Diabetes Association 2026 Scientific Sessions and published in the *Journal of the American Heart Association*, analyzed data from over 26,000 patients.

## Key Findings at a Glance

**The study found substantial reductions in risk for patients on GLP-1 receptor agonists (GLP-1RAs):**

- **17% lower risk** of venous thromboembolism (blood clots)
- **31% lower risk** of pulmonary embolism (a dangerous lung clot)
- **21% lower likelihood** of emergency department visits
- **44% decreased risk** of all-cause mortality (death from any cause)
- **Modest decrease** in stroke risk (13% relative risk reduction)
- **Nonsignificant trend** for heart attack risk (14% relative risk reduction)

## Study Details

The investigation drew on data from the OneFlorida+ network, covering the years 2014 to 2024.

- **Total participants:** 26,408 adults
- **Matched groups:** 13,204 patients taking a GLP-1RA were compared with 13,204 similar patients not taking the medication.
- **Average profile:** Age 55, 73% women, 53% non-Hispanic white, average BMI of 37 (class 3 obesity).
- **Autoimmune diseases:** These were grouped by organ system, including skin, gastrointestinal, endocrine, musculoskeletal, systemic, nervous system, blood, and cardiovascular conditions.

## Important Limitations

The study's authors caution that this is an observational study and therefore **cannot prove causation.**

- Autoimmune diseases were treated as a broad group, which may mask differences between specific conditions.
- **Possible confounding factors**—such as weight loss or improved blood sugar control from the drugs—could influence the results.
- **Further research is needed** to confirm these findings and understand the underlying mechanisms.